Shamis & Gentile, P.A. is investigating claims on behalf of investors of Inspire Medical Systems (“Inspire Medical Systems” or the “Company”) (INSP). Impacted investors are advised to contact the firm now.
The investigation concerns whether Inspire Medical Systems and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
The investigation focuses on whether Inspire Medical Systems misled investors regarding the commercial launch and market adoption of its Inspire V system, as well as the competitive impact of GLP-1 weight-loss drugs on its core business. On Aug. 4, 2025, after market close, Inspire Medical Systems announced disappointing second quarter results, including admissions that the U.S. launch of the Inspire V system was “progressing slower than expected” and that the Company was pushing out its transition timeline. Management also dramatically cut full-year 2025 guidance, lowering revenue expectations to $900–910 million from a prior range of $940–955 million and reducing EPS guidance to $0.40–$0.50 from $2.20–$2.30.
On this news, Inspire Medical Systems’ stock price fell $42.00 per share, or approximately 32%, to close at $88.00 on Aug. 5, 2025, erasing hundreds of millions of dollars in market capitalization.
The investigation is also examining insider selling. During the relevant period, several senior executives reportedly sold significant amounts of stock while the stock price remained elevated, including sales by the CEO, CFO and Executive Vice President in February and March 2025.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
